Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | FPR1 | P21462 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868421 | 1.00 | FASN (0.34) | FASNFPR1FPR2CTSDBACE1 | |
| SCHEMBL10121170 | 0.90 | CNR1 (0.35) | CNR1CNR2PTGS2 | |
| SCHEMBL868828 | 0.90 | CNR1 (0.35) | CNR1CNR2PTGS2 | |
| SCHEMBL13822295 | 0.81 | — | — | |
| SCHEMBL867844 | 0.79 | FASN (0.38) | FASNFPR1FPR2CTSDBACE1 | |
| SCHEMBL10195060 | 0.75 | LMNA (0.36) | — | |
| SCHEMBL12632679 | 0.75 | FASN (0.35) | FASNFPR1FPR2CTSDBACE1 | |
| SCHEMBL867974 | 0.75 | CNR1 (0.33) | CNR1CNR2PTGS2 | |
| SCHEMBL868368 | 0.72 | PGR (0.37) | — | |
| SCHEMBL12633250 | 0.72 | GPBAR1 (0.35) | FASNFPR1FPR2CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987476-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-8987476-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8680299-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-8680299-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-20130137573-A1 | HERBICIDAL COMPOSITIONS COMPRISING, AND METHODS OF USE OF, HERBICIDALLY ACTIVE PYRANDIONES | SYNGENTA LIMITED (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137573-A1 | HERBICIDAL COMPOSITIONS COMPRISING, AND METHODS OF USE OF, HERBICIDALLY ACTIVE PYRANDIONES | SYNGENTA LIMITED (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | CYP1A1, CYP2E1, CYP1B1 | FASN 668/4885FPR1 2192/4885FPR2 2918/4885 |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | CYP1A1, CYP2E1, GSTO1 | FASN 1182/4885FPR1 2598/4885FPR2 3414/4885 |
| US-20130137573-A1 | HERBICIDAL COMPOSITIONS COMPRISING, AND METHODS OF USE OF, HERBICIDALLY ACTIVE PYRANDIONES | FOXM1, ARSA, RPS21 | FASN 2886/4885FPR1 4190/4885FPR2 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.